Open Access
Research Article
Volume 24, 2017
Article Number 12
Number of page(s) 10
Published online 03 April 2017
  1. Choi JH, Jonsson-Schmunk K, Qiu X, Shedlock DJ, Strong J, Xu JX, Michie KL, Audet J, Fernando L, Myers MJ, Weiner D, Bajrovic I, Tran LQ, Wong G, Bello A, Kobinger GP, Schafer SC, Croyle MA. 2015. A single dose respiratory recombinant adenovirus-based vaccine provides long-term protection for non-human primates from lethal Ebola infection. Molecular Pharmacology, 12(8), 2712–2731. [CrossRef] [Google Scholar]
  2. Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, Sette A, Maewal A, EI Bissati K, Zhou Y, Suzuki Y, Lee D, Woods S, Sommerville C, Henriquez FL, Roberts CW, McLeod R. 2012. Toxoplasma gondii HLA-B*0702-restricted GRA7(20–28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-gamma and reduces parasite burden in HLA-B*0702 mice. Human Immunology, 73(1) 1–10. [CrossRef] [PubMed] [Google Scholar]
  3. Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, Sette A, Maewal A, McLeod R. 2010. Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+ T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii. Immunome Research, 6, 12. [CrossRef] [PubMed] [Google Scholar]
  4. Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, Sette A, Maewal A, McLeod R. 2011. Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201. Vaccine, 29(4), 754–762. [CrossRef] [PubMed] [Google Scholar]
  5. Cong H, Yuan Q, Zhao Q, Zhao L, Yin H, Zhou H, He S, Wang Z. 2014. Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice. Parasites & Vectors, 7, 145. [CrossRef] [PubMed] [Google Scholar]
  6. Dardé ML, Bouteille B, Pestre-Alexandre M. 1992. Isoenzyme analysis of 35 Toxoplasma gondii isolates and the biological and epidemiological implications. Journal of Parasitology, 78(5), 786–794. [CrossRef] [PubMed] [Google Scholar]
  7. Derouin F, Pelloux H. 2008. Prevention of toxoplasmosis in transplant patients. Clinical Microbiology and Infection, 14(12), 1089–1101. [CrossRef] [Google Scholar]
  8. Edele F, Dudda JC, Bachtanian E, Jakob T, Pircher H, Martin SF. 2014. Efficiency of dendritic cell vaccination against B16 melanoma depends on the immunization route. PLoS One, 9(8), e105266. [CrossRef] [PubMed] [Google Scholar]
  9. Fiorino F, Pettini E, Pozzi G, Medaglini D, Ciabattini A. 2013. Prime-boost strategies in mucosal immunization affect local IgA production and the type of th response. Frontiers in Immunology, 4, 128. [CrossRef] [PubMed] [Google Scholar]
  10. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. 1993. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proceedings of the National Academy of Sciences of the United States of America, 90(24), 11478–11482. [CrossRef] [PubMed] [Google Scholar]
  11. Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, McElrath MJ, Robertson M, Kublin J, Corey L, HVTN 503/Phambili study team. 2014. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infectious Diseases, 14(5), 388–396. [CrossRef] [PubMed] [Google Scholar]
  12. Henriquez FL, Woods S, Cong H, McLeod R, Roberts CW. 2010. Immunogenetics of Toxoplasma gondii informs vaccine design. Trends in Parasitology, 26(11), 550–555. [CrossRef] [PubMed] [Google Scholar]
  13. Innes EA. 2010. A brief history and overview of Toxoplasma gondii. Zoonoses and Public Health, 57(1), 1–7. [CrossRef] [PubMed] [Google Scholar]
  14. Johnson J, Suzuki Y, Mack D, Mui E, Estes R, David C, Skamene E, Forman J, McLeod R. 2002. Genetic analysis of influences on survival following Toxoplasma gondii infection. International Journal for Parasitology, 32, 179–185. [CrossRef] [PubMed] [Google Scholar]
  15. Jongert E, Lemiere A, Van Ginderachter J, De Craeye S, Huygen K, D’Souza S. 2010. Functional characterization of in vivo effector CD4(+) and CD8(+) T cell responses in acute toxoplasmosis: an interplay of IFN-gamma and cytolytic T cells. Vaccine, 28(13), 2556–2564. [CrossRef] [PubMed] [Google Scholar]
  16. Karen KA, Deal C, Adams RJ, Nielsen C, Ward C, Espinosa DA, Xie J, Zavala F, Ketner G. 2015. A replicating adenovirus capsid display recombinant elicits antibodies against Plasmodium falciparum sporozoites in Aotus nancymaae monkeys. Infection and Immunity, 83(1), 268–275. [CrossRef] [PubMed] [Google Scholar]
  17. Kijlstra A, Petersen E. 2014. Epidemiology, pathophysiology, and the future of ocular toxoplasmosis. Ocular Immunology and Inflammation, 22(2), 138–147. [CrossRef] [PubMed] [Google Scholar]
  18. Kweon MN. 2014. Recent progress in mucosal immunology and vaccine development. Experimental & Molecular Medicine, 46, e86. [CrossRef] [PubMed] [Google Scholar]
  19. Lim SS, Othman RY. 2014. Recent advances in Toxoplasma gondii immunotherapeutics. Korean Journal of Parasitology, 52, 581–593. [CrossRef] [Google Scholar]
  20. Liu Q, Wang F, Wang G, Zhao Q, Min J, Wang S, Cong H, Li Y, He S, Zhou H. 2014. Toxoplasma gondii: immune response and protective efficacy induced by ROP16/GRA7 multicomponent DNA vaccine with a genetic adjuvant B7–2. Human Vaccines & Immunotherapeutics, 10(1), 184–191. [CrossRef] [PubMed] [Google Scholar]
  21. Li XZ, Lv L, Zhang X, Anchang KY, Abdullahi AY, Tu L, Wang X, Xia L, Zhang XX, Feng W, Lu C, Li S, Yuan ZG. 2016. Recombinant canine adenovirus type-2 expressing TgROP16 provides partial protection against acute Toxoplasma gondii infection in mice. Infection Genetics and Evolution, 45, 447–453. [CrossRef] [Google Scholar]
  22. Li XZ, Wang XH, Xia LJ, Weng YB, Hernandez JA, Tu LQ, Li LT, Li SJ, Yuan ZG. 2015. Protective efficacy of recombinant canine adenovirus type-2 expressing TgROP18 (CAV-2-ROP18) against acute and chronic Toxoplasma gondii infection in mice. BMC Infectious Diseases, 15, 114. [CrossRef] [PubMed] [Google Scholar]
  23. Lycke N. 2012. Recent progress in mucosal vaccine development: potential and limitations. Nature reviews. Immunology, 12(8), 592–605. [PubMed] [Google Scholar]
  24. Ma C, Li Y, Wang L, Zhao G, Tao X, Tseng CT, Zhou Y, Du L, Jiang S. 2014. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine, 32(18), 2100–2108. [CrossRef] [PubMed] [Google Scholar]
  25. Malvey EN, Jenkins MK, Mueller DL. 1998. Peripheral immune tolerance blocks clonal expansion but fails to prevent the differentiation of Th1 cells. Journal of Immunology, 161(5), 2168–2177. [Google Scholar]
  26. McLeod R, Eisenhauer P, Mack D, Brown C, Filice G, Spitalny G. 1989. Immune responses associated with early survival after peroral infection with Toxoplasma gondii. Journal of Immunology, 142, 3247–3255. [Google Scholar]
  27. Mendes EA, Caetano BC, Penido ML, Bruna-Romero O, Gazzinelli RT. 2011. MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8 (+) T lymphocytes. Vaccine, 29(27), 4476–4484. [CrossRef] [PubMed] [Google Scholar]
  28. Meng M, He S, Zhao G, Bai Y, Zhou H, Cong H, Lu G, Zhao Q, Zhu XQ. 2012. Evaluation of protective immune responses induced by DNA vaccines encoding Toxoplasma gondii surface antigen 1 (SAG1) and 14–3-3 protein in BALB/c mice. Parasites & Vectors, 5, 273. [CrossRef] [PubMed] [Google Scholar]
  29. Montoya JG, Liesenfeld O. 2004. Toxoplasmosis. Lancet, 363(9425), 1965–1976. [CrossRef] [PubMed] [Google Scholar]
  30. Paquet C, Yudin MH. 2013. Toxoplasmosis in pregnancy: prevention, screening, and treatment. Journal of Obstetrics and Gynaecology Canada, 35(1), 78–81. [CrossRef] [Google Scholar]
  31. Pifer R, Yarovinsky F. 2011. Innate responses to Toxoplasma gondii in mice and humans. Trends in Parasitology, 27(9), 388–393. [CrossRef] [PubMed] [Google Scholar]
  32. Rosa DS, Ribeiro SP, Almeida RR, Mairena EC, Kalil J, Cunha-Neto E. 2011. A recombinant adenovirus encoding multiple HIV-1 epitopes induces stronger CD4 T cell responses than a DNA vaccine in mice. Vaccines and Vaccination, 2(4), 1–17. [Google Scholar]
  33. Sabin AB. 1941. Toxoplasmic encephalitis in children. Journal of the American Medical Association, 116, 801–807. [CrossRef] [Google Scholar]
  34. Schlüter D, Deckert-Schluter M, Lorenz E, Meyer T, Rollinger M, Bogdan C. 1999. Inhibition of inducible nitric oxide synthase exacerbates chronic cerebral toxoplasmosis in Toxoplasma gondii-susceptible C57BL/6 mice but does not reactivate the latent disease in T. gondii-resistant BALB/c mice. Journal of Immunology, 162, 3512–3518. [Google Scholar]
  35. Singh S, Vedi S, Li W, Samrat SK, Kumar R, Agrawal B. 2014. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum. Vaccine, 32(23), 2712–2721. [CrossRef] [PubMed] [Google Scholar]
  36. Sullivan WJ, Jeffers V. 2012. Mechanisms of Toxoplasma gondii persistence and latency. FEMS Microbiology Reviews, 36, 717–733. [CrossRef] [PubMed] [Google Scholar]
  37. Valdenegro-Vega VA, Crosbie P, Vincent B, Cain KD, Nowak BF. 2013. Effect of immunization route on mucosal and systemic immune response in Atlantic salmon (Salmo salar). Veterinary Immunology and Immunopathology, 151(1–2), 113–123. [CrossRef] [PubMed] [Google Scholar]
  38. Verma R, Khanna P. 2013. Development of Toxoplasma gondii vaccine: A global challenge. Human Vaccines & Immunotherapeutics, 9(2), 291–293. [CrossRef] [PubMed] [Google Scholar]
  39. Xiang Z, Ertl HC. 1999. Induction of mucosal immunity with a replication-defective adenoviral recombinant. Vaccine, 17(15–16), 2003–2008. [CrossRef] [PubMed] [Google Scholar]
  40. Yin H, Zhao L, Wang T, Zhou H, He S, Cong H. 2015. A Toxoplasma gondii vaccine encoding multistage antigens in conjunction with ubiquitin confers protective immunity to BALB/c mice against parasite infection. Parasites & Vectors, 8, 498. [CrossRef] [PubMed] [Google Scholar]
  41. Yu L, Yamagishi J, Zhang S, Jin C, Aboge GO, Zhang H, Zhang G, Tanaka T, Fujisaki K, Nishikawa Y, Xuan X. 2012. Protective effect of a prime-boost strategy with plasmid DNA followed by recombinant adenovirus expressing TgAMA1 as vaccines against Toxoplasma gondii infection in mice. Parasitology International, 61(3), 481–486. [CrossRef] [PubMed] [Google Scholar]
  42. Zhang M, Zhao L, Song J, Li Y, Zhao Q, He S, Cong H. 2013. DNA vaccine encoding the Toxoplasma gondii bradyzoite-specific surface antigens SAG2CDX protect BALB/c mice against type II parasite infection. Vaccine, 31(41), 4536–4540. [CrossRef] [PubMed] [Google Scholar]
  43. Zhao L, Zhang M, Cong H. 2013. Advances in the study of HLA-restricted epitope vaccines. Human Vaccines & Immunotherapeutics, 9(12), 2566–2577. [CrossRef] [PubMed] [Google Scholar]
  44. Zhou H, Min J, Zhao Q, Gu Q, Cong H, Li Y, He S. 2012. Protective immune response against Toxoplasma gondii elicited by a recombinant DNA vaccine with a novel genetic adjuvant. Vaccine, 30(10), 1800–1806. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.